Frederick R Blattner
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2015First federal award
$12.6MFederal grants as PI15 awards
8Patents grantedLatest Apr 30, 2024
153Papers34,935 citations
Federal awards and patents by year
AwardsPatents
15 awards · $12.6M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Jun 17, 2022 | NIH | SBIR Phase II Production of antibody therapeutic fragments by reduced genome E. coli in continuous culture | $962K | SCARAB GENOMICS LLC |
| Jun 7, 2021 | NIH | SBIR Phase II Production of antibody therapeutic fragments by reduced genome E. coli in continuous culture | $945K | SCARAB GENOMICS LLC |
| Feb 10, 2021 | NIH | SBIR Phase II Toxoid adjuvant CRM197 production in a stable reduced genome E. coli strain | $1.0M | SCARAB GENOMICS LLC |
| Jul 13, 2020 | NIH | SBIR Phase II Production of antibody therapeutic fragments by reduced genome E. coli in continuous culture | $1.0M | SCARAB GENOMICS LLC |
| Jun 26, 2020 | NIH | SBIR Phase II Lysis-free extraction of biopharmaceuticals from the periplasm of Clean Genome E. coli | $738K | SCARAB GENOMICS LLC |
| Feb 14, 2020 | NIH | SBIR Phase II Toxoid adjuvant CRM197 production in a stable reduced genome E. coli strain | $1.0M | SCARAB GENOMICS LLC |
| Jun 20, 2019 | NIH | SBIR Phase II Lysis-free extraction of biopharmaceuticals from the periplasm of Clean Genome E. coli | $911K | SCARAB GENOMICS LLC |
| Mar 20, 2019 | NIH | SBIR Phase II Toxoid adjuvant CRM197 production in a stable reduced genome E. coli strain | $1.0M | SCARAB GENOMICS LLC |
| Dec 12, 2018 | NIH | SBIR Phase II Lysis-free extraction of biopharmaceuticals from the periplasm of Clean Genome E. coli | $156K | SCARAB GENOMICS LLC |
| Jun 29, 2018 | NIH | SBIR Phase II Increasing available choices for conjugate vaccine technology by producing carrier proteins in Scarab Genomics’ reduced genome E. coli strains | $707K | SCARAB GENOMICS LLC |
| Jul 24, 2017 | NIH | SBIR Phase II Increasing available choices for conjugate vaccine technology by producing carrier proteins in Scarab Genomics’ reduced genome E. coli strains | $878K | SCARAB GENOMICS LLC |
| Jun 6, 2017 | NIH | SBIR Phase II Characterization of a low mutation rate E. coli in extended fermentation | $864K | SCARAB GENOMICS LLC |
| Dec 14, 2016 | NIH | SBIR Phase II Increasing available choices for conjugate vaccine technology by producing carrier proteins in Scarab Genomics’ reduced genome E. coli strains | $154K | SCARAB GENOMICS LLC |
| May 19, 2016 | NIH | SBIR Phase II Characterization of a low mutation rate E. coli in extended fermentation | $1.6M | SCARAB GENOMICS LLC |
| Mar 17, 2015 | NIH | SBIR Phase II Toxoid adjuvant CRM197 production in a stable reduced genome E. coli strain | $729K | SCARAB GENOMICS LLC |
9 patents as inventor
- US 10604736SCARAB GENOMICS LLCMar 31, 2020
- US 11142745SCARAB GENOMICS LLCOct 12, 2021
- US 11174284SCARAB GENOMICS LLCNov 16, 2021
- US 11667944SCARAB GENOMICS LLCJun 6, 2023
- US 11970725SCARAB GENOMICS LLCApr 30, 2024
- US 9340791SCARAB GENOMICS LLCMay 17, 2016
- US 9902965SCARAB GENOMICS LLCFeb 27, 2018
- US 9914905SCARAB GENOMICS LLCMar 13, 2018
- US SCARAB GENOMICS LLC—
Matched by the first inventor’s name and the patent’s company.
Peer ranks
Federal funding#35
Awards as PI#46
Patents#6
Companies
- SCARAB GENOMICS LLCLinked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.